EE507 Integrated Budget Impact Analysis of Introducing Selpercatinib As a Tumor-Agnostic Treatment Option for Patients with RET-Altered Solid Tumors in the United States
Abstract
Authors
N.R. Bhandari F.N. Cinfio A. Gilligan J. Myers A. Ale-Ali L. Smolen